Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study

Fig. 3The alternative text for this image may have been generated using AI.

The relationship between genomic mutations and the efficacy of neoadjuvant therapy was explored through next-generation sequencing analysis of blood and tumor tissue samples. a Genomic profile at baseline based on ctDNA in 30 patients (mutation frequency ≥4%); b Analysis of differences in blood tumor mutation burden (bTMB) among groups at baseline. c Changes in bTMB among groups during neoadjuvant therapy. d Baseline genomic mutation profile based on tumor tissue samples. e The relationship between STK11 mutations and survival was validated. f Changes in gene mutations during neoadjuvant therapy were categorized into four patterns: gain (mutations appearing after treatment), increase (mutation frequency rising after treatment), loss (mutations eliminated after treatment), and decrease (mutation frequency decreasing after treatment). pCR, pathological complete response; bTMB, blood tumor mutational burden

Back to article page